Uniphar (LON:UPR) Receives “Buy” Rating from Shore Capital

Uniphar (LON:UPRGet Free Report)‘s stock had its “buy” rating reaffirmed by Shore Capital in a note issued to investors on Tuesday, MarketBeat.com reports.

Uniphar Stock Up 1.6 %

Shares of Uniphar stock opened at GBX 196.57 ($2.45) on Tuesday. Uniphar has a 1 year low of GBX 163 ($2.03) and a 1 year high of GBX 256 ($3.19). The firm has a market cap of £536.68 million, a price-to-earnings ratio of 1,404.07 and a beta of 0.75. The company has a 50-day moving average of GBX 175.14 and a 200 day moving average of GBX 198.72. The company has a debt-to-equity ratio of 119.43, a current ratio of 0.90 and a quick ratio of 0.60.

About Uniphar

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Recommended Stories

Receive News & Ratings for Uniphar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniphar and related companies with MarketBeat.com's FREE daily email newsletter.